2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
40
Gastro-enteropancreatic neuroendocrine tumor
8
Paraganglioma
6
Meningioma
6
Pheochromocytoma
5
Carcinoma, Neuroendocrine
4
Neuroblastoma
3
Carcinoid Tumor
3
Adenoma, Islet Cell
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms
2
Medulloblastoma
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Carcinoma, Merkel Cell
2
Carcinoma, Medullary
2
Stomach Neoplasms
1
Somatostatinoma
1
Somatostatin Receptor-positive Neuroendocrine Tumor
1
Somatostatin Receptor-positive GEP-NET
1
Small Cell Lung Carcinoma
1
Serotonin Syndrome
1
Sarcoma, Synovial
1
Recurrence
1
Pituitary Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Diseases
1
Interventions
Adrenalectomy
5
Radiosurgery
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Fluorodeoxyglucose F18
2
FAPI-46
2
pertuzumab
1
olaparib
1
lutetium Lu 177 dotatate
1
iodophenyl metomidate
1
camrelizumab
1
apatinib
1
X-Rays
1
Surgical Procedures, Operative
1
Radiofrequency Ablation
1
Quality of Life
1
Patient Reported Outcome Measures
1
Observation
1
Nephrectomy
1
N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride
1
Molecular Diagnostic Techniques
1
Mitotane
1
Immunotherapy
1
Gefitinib
1
Floxuridine
1
Erlotinib Hydrochloride
1
Endosonography
1
Endoscopic Ultrasound-Guided Fine Needle Aspiration
1
Drug Therapy
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adrenal Gland Neoplasms
×
lutetium Lu 177 dotatate
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled